Das medulläre Schilddrüsenkarzinom und die multiple endokrine Neoplasie Typ 2

Das medulläre Schilddrüsenkarzinom (medullary thyroid carcinoma, MTC) betrifft nur 3 % aller Schilddrüsenkarzinome: 75 % als sporadisches MTC (sMTC) und 25 % als hereditäres MTC (hMTC) im Rahmen der multiplen endokrinen Neoplasie Typ 2 (MEN2). Eine frühzeitige Diagnose ist durch die Bestimmung des Tumormarkers Calcitonin (Ctn) bei der Abklärung der Struma nodosa und den Nachweis der Mutation im RET-Protoonkogen in den MEN2-Familien möglich. Durch die adäquate Operation ist eine Heilung im Frühstadium möglich; im Spätstadium ist die Tyrosinkinase-Inhibitor-Therapie eine Option.

Abstract

Medullary thyroid carcinoma (MTC) is a rare malignancy and compromises only 3 % of all thyroid carcinomas. MTC cells secret calcitonin, which serves as a sensitive tumor marker for screening and follow-up of MTC. Calcitonin screening in patients with nodular goiter allows for early diagnosis of MTC and surgical curative treatment. In 25 % of patients MTC occurs as an integral part of multiple endocrine neoplasia type 2 (MEN2), an autosomal dominant inherited tumor syndrome. It is caused by germline mutations in the RET protooncogene. In gene carriers early diagnosis and treatment through prophylactic thyroidectomy is possible. MTC is a slowly growing tumor with a good prognosis and 5 and 10 year survival rates up to 80 and 60 %. In the follow-up a dynamic risk stratification allows for a personalized disease management. In symptomatic and progressive metastasizing MTC tyrosine kinase inhibitors are an effective therapy.

Schlüsselwörter

medulläres Schilddrüsenkarzinom - multiple endokrine Neoplasie Typ 2 - RET-Protoonkogen - Calcitonin - Tyrosinkinase-Inhibitor

Key words

medullary thyroid carcinoma - multiple endocrine neoplasia type 2 - RET-protooncogene - calcitonin - tyrosine kinase inhibitor

Publication History

Article published online:
07 July 2020

• Literatur

• 1 Wells Jr SA, Asa SL, Dralle H. et al Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567-610 . doi:10.1089/thy.2014.0335
• 2 Elisei R, Alevizaki M, Conte-Devolx B. et al 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J 2013; 1: 216-231 . doi:10.1159/000346174
• 3 Dralle H, Musholt TJ, Schabram J. et al German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg 2013; 398: 347-375 . doi:10.1007/s00423-013-1057-6
• 4 Costante G, Durante C, Francis Z. et al Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009; 5: 35-44 . doi:10.1038/ncpendmet1023
• 5 Frank-Raue K, Machens A, Leidig-Bruckner G. et al Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid 2013; 23: 294-300 . doi:10.1089/thy.2012.0236
• 6 Karges W, Dralle H, Raue F. et al Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58 . doi:10.1055/s-2004-815727
• 7 Elisei R, Romei C. Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. Thyroid Res 2013; 6 (01) S2 . doi:10.1186/1756-6614-6-S1-S2
• 8 Kratzsch J, Petzold A, Raue F. et al Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem 2011; 57: 467-474 . doi:10.1373/clinchem.2010.151688
• 9 Kahaly GJ, Algeciras-Schimnich A, Davis TE. et al United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin. Clin Chem 2017; 63: 1489-1496 . doi:10.1373/clinchem.2016.270009
• 10 Mian C, Perrino M, Colombo C. et al Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab 2014; 99: 1656-1664 . doi:10.1210/jc.2013-4088
• 11 Frank-Raue K, Schott M, Raue F. et al Recommendation for Calcitonin Screening in Nodular Goiter. Dtsch Med Wochenschr 2018; 143: 1065-1069 . doi:10.1055/a-0585-8097
• 12 Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2655-2663 . doi:10.1210/jc.2009-2368
• 13 Mucha L, Leidig-Bruckner G, Frank-Raue K. et al Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. Clin Endocrinol (Oxf) 2017; 87: 320-326 . doi:10.1111/cen.13386
• 14 Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev 2019; 40: 1573-1604 . doi:10.1210/er.2019-00007
• 15 Machens A, Gimm O, Ukkat J. et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 2000; 88: 1909-1915
• 16 Randle RW, Balentine CJ, Leverson GE. et al Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017; 161: 137-146 . doi:10.1016/j.surg.2016.04.053
• 17 Lindsey SC, Ganly I, Palmer F. et al Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 2015; 25: 242-249 . doi:10.1089/thy.2014.0277
• 18 Yang JH, Lindsey SC, Camacho CP. et al Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer. Clin Endocrinol (Oxf) 2015; 83: 938-942 . doi:10.1111/cen.12657
• 19 Raue F, Frank-Raue K. Long-Term Follow-up in Medullary Thyroid Carcinoma. Recent Results Cancer Res 2015; 204: 207-225 . doi:10.1007/978-3-319-22542-5_10
• 20 Leidig-Bruckner G, Bruckner T, Raue F. et al Long-Term Follow-Up and Treatment of Postoperative Permanent Hypoparathyroidism in Patients with Medullary Thyroid Carcinoma: Differences in Complete and Partial Disease. Horm Metab Res 2016; 48 (12) 806-813 . doi:10.1055/s-0042-118181
• 21 Laure Giraudet A, Al Ghulzan A, Auperin A. et al Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158: 239-246 . doi:10.1530/EJE-07-0667
• 22 Hadoux J, Pacini F, Tuttle RM. et al Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol 2016; 4: 64-71 . doi:10.1016/S2213-8587(15)00337-X
• 23 Vogel T, Wendler J, Frank-Raue K. et al Bone metastases in medullary thyroid carcinoma: high morbidity and poor prognosis associated with osteolytic morphology. J Clin Endocrinol Metab 2020; DOI: 10.1210/clinem/dgaa077.